Skip to main content
. 2019 Oct 17;116(45):22730–22736. doi: 10.1073/pnas.1911385116

Fig. 3.

Fig. 3.

ERBB2 extracellular domain mutant cervical cancers are sensitive to ERBB2 inhibition by afatinib or neratinib in vitro and in vivo. (A and B) Mean IC50 values of ERBB2-mutated cervical carcinoma (CC) compared to ERBB2 wild-type CC cell lines (P < 0.0001) in response to afatinib (A) and to neratinib (B). (C) Tumor growth inhibition and (D) overall survival (OS) in response to afatinib and neratinib in a representative Her2/neu-mutated xenograft (CVX-4). The control group received vehicle per os (PO), the afatinib group 25 mg/kg afatinib, and the neratinib group 40 mg/kg neratinib (tumor volume [TV] control vs. afatinib P = 0.001 and control vs. neratinib P = 0.0002, OS control vs. afatinib P = 0.0001 and OS control vs. neratinib P = 0.0001).